Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Use of tAN® in Alcohol Withdrawal Management

NCT: NCT06771037 · TERMINATED

NCT IDNCT06771037
StatusTERMINATED
Start Date2025-04-21
Completion2025-12-15
SponsorErin Takemoto (OTHER)
First posted
Last updated

Brief Summary

This research study is being conducted to learn if Transcutaneous Auricular Neurostimulation (tAN®) may be effective in treating alcohol withdrawal syndrome. Transcutaneous Auricular Neurostimulation (tAN®) works by delivering small electrical stimulations to the Vagus and Trigeminal nerves. This study will be conducted over the course of five days. Participants will be enrolled within 24 hours of entering treatment for alcohol withdrawal management. A total of 60 individuals will be enrolled and randomly assigned to either active (treatment with the device + treatment as usual) or sham (treatment as usual) group. Data will be collected on alcohol craving, use of comfort medications, sleep, and mood.

Frequently Asked Questions

What is Use of tAN® in Alcohol Withdrawal Management?

Use of tAN® in Alcohol Withdrawal Management is a clinical trial registered under NCT06771037. Current status: TERMINATED.

What is the status of NCT06771037?

The current status of NCT06771037 (Use of tAN® in Alcohol Withdrawal Management) is: TERMINATED.

When did Use of tAN® in Alcohol Withdrawal Management start?

Use of tAN® in Alcohol Withdrawal Management started on 2025-04-21.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.